Cargando…
SRF617 Is a Potent Inhibitor of CD39 with Immunomodulatory and Antitumor Properties
CD39 (ENTPD1) is a key enzyme responsible for degradation of extracellular ATP and is upregulated in the tumor microenvironment (TME). Extracellular ATP accumulates in the TME from tissue damage and immunogenic cell death, potentially initiating proinflammatory responses that are reduced by the enzy...
Autores principales: | Warren, Michael C., Matissek, Stephan, Rausch, Matthew, Panduro, Marisella, Hall, Richard J., Dulak, Austin, Brennan, David, Yekkirala, Sonia Das, Koseoglu, Secil, Masia, Ricard, Yang, Yu, Reddy, Navamallika, Prenovitz, Robert, Strand, Jamie, Zaidi, Tauqueer, Devereaux, Erik, Foissac, Célia Jacoberger, Stagg, John, Lee, Benjamin H., Holland, Pamela, Palombella, Vito J., Lake, Andrew C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AAI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10579980/ https://www.ncbi.nlm.nih.gov/pubmed/37219538 http://dx.doi.org/10.4049/immunohorizons.2200089 |
Ejemplares similares
-
Adenosine A2A receptor is a tumor suppressor of NASH-associated hepatocellular carcinoma
por: Allard, Bertrand, et al.
Publicado: (2023) -
The Fully human anti-CD47 antibody SRF231 exerts dual-mechanism antitumor activity via engagement of the activating receptor CD32a
por: Peluso, Marisa O, et al.
Publicado: (2020) -
SRF for Muon Colliders
por: Padamsee, H
Publicado: (2000) -
NLK is required for Ras/ERK/SRF/ELK signaling to tune skeletal muscle development by phosphorylating SRF and antagonizing the SRF/MKL pathway
por: Li, Shang-Ze, et al.
Publicado: (2022) -
Developments on SRF coatings at CERN
por: Sublet, Alban, et al.
Publicado: (2015)